News & Events about Aura Biosciences Inc.
Business Wire
2 months ago
Aura Biosciences, Inc. (Aura) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a...
Business Wire
7 months ago
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan (AU-011), for the...
Market News Video
7 months ago
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So lets look at two noteworthy recent insider buys...
Ticker Report
9 months ago
Aura Biosciences, Inc. (NASDAQ:AURA Get Rating) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 333,000 shares, a growth of 73.3% from the March 15th total of 192,200 shares. Based on an average trading volume of 28,900 ...